title: Current status and future prospects of peptide-based cancer vaccines.
abstract: Cancer immunotherapy has attracted attention worldwide owing to the recent development of immune checkpoint inhibitors. However, these therapies have shown limited efficacy, and further advancements are needed before these modalities can progress to widespread use. Immune checkpoint inhibitors are a type of nonspecific cancer immunotherapy, and antitumor effects are only observed when cancer-specific T cells are found within the nonspecifically activated T-cell group. In order to facilitate the development of potent immunotherapies, selective enhancement of cancer-specific T cells is essential. In this report, we discuss current and future perspectives, including the latest clinical trials of cancer-specific immunotherapies, particularly cancer peptide vaccines.
authors.affiliation: Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Wada
authors.affiliation: Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
authors.forename: Erika
authors.initials: E
authors.lastname: Yada
authors.affiliation: Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
authors.forename: Junya
authors.initials: J
authors.lastname: Ohtake
authors.affiliation: Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Fujimoto
authors.affiliation: Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
authors.forename: Hidemi
authors.initials: H
authors.lastname: Uchiyama
authors.affiliation: Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
authors.forename: Shintaro
authors.initials: S
authors.lastname: Yoshida
authors.affiliation: Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Sasada
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D002986:Clinical Trials as Topic; D061025:Costimulatory and Inhibitory T-Cell Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D022223:Vaccines, Subunit / Q000276:immunology*
chemical_list: D019496:Cancer Vaccines; D061025:Costimulatory and Inhibitory T-Cell Receptors; D022223:Vaccines, Subunit
keywords: T-cell therapy; adaptive immunity; adjuvant; cancer immunotherapy; clinical trials; peptide vaccines; tumor antigens